Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07235514

Anesthesia Management in Endovascular Therapy for Ischemic Stroke - 2

The goal of this clinical trial is to learn what is the best anesthetic management in participants with severe stroke that require a medical intervention called mechanical thrombectomy (MT) done to open the occluded brain vessel.

The main question it aims to answer is:

• Is general anesthesia (GA) better than procedural sedation (PS) for improving functional performance and decrease dependance in daily life 3 months after stroke?

GA (a non-arousable state induced by anesthetic medications that require respiratory assistance) or PS (a state of reduced arousal induced by lesser dose of anesthetic medications that do not require respiratory assistance) are both used for MT. GA enables strict immobility that could facilitate the conduct of MT but lessen blood pressure and blood flow in the brain. PS provides less drop in blood pressure but MT could be more difficult due to possible movement and breathing may be decreased.

Researchers will compare GA with PS to see which one is better for MT success and for the functional consequences of stroke.

Participants will be treated with GA or PS for the intervention of MT and will be followed by researchers during their hospital stay and asked by a telephone interview how is their functional status 3 months after stroke.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Clermont-Ferrand

Clermont-Ferrand, France

Location contact

Lise Laclautre

CONTACT

[email protected]

0473754963

Russell Chabanne

PRINCIPAL_INVESTIGATOR

About this study

Mechanical thrombectomy (MT) has significantly improved the outcome of anterior circulation large vessel occlusion stroke. The MT procedure could require management by a dedicated anesthesia team to ensure safety and immobility of these frail patients, in order to quickly restore cerebral perfusion and prevent procedural complications. The anesthetic strategy (general anesthesia with tracheal intubation (GA) or procedural sedation with spontaneous ventilation (PS)) can impact the conduct of the procedure and influence the functional outcome. GA ensures immobility and airway control, but can alter blood pressure (BP). PS provides better control of BP but may be associated with respiratory failure and movements that could interfere with intra-arterial navigation.

Three European single-center randomized controlled trials (RCTs) found no difference between GA and PS for their respective primary endpoints. These three trials were pooled in an individual patient data meta-analysis that evaluated functional outcome (modified Rankin Scale mRS) at 3 months as the primary endpoint. 368 patients were included, and GA was associated with a better functional outcome (mean mRS score was 2.8 (95% CI, 2.5-3.1) in the GA group vs. 3.2 (95% CI, 3.0-3.5) in the PS group (difference, 0.43 [95% CI, 0.03-0.83])). The main limitations of this trial were 1) the small sample size (3 small single-center trials), 2/ a possible center effect with over-representation of one trial on the primary endpoint, and 3/ a highly selected population (exclusion of less severe patients (NIHSS<10), stroke presentation > 8 hours and wake up stroke).

Two French multicenter RCTs have recently been published. The GASS trial included 345 patients in four centers with dedicated GA and PS protocols. There was no difference in the primary endpoint, which was functional independence (mRS 0 to 2) at three months (36% for PS vs. 38% for GA (RR, 0.91 [95% CI, 0.69 to 1.19], p = 0.47)). The AMETIS trial included 273 patients in 10 centers with no specified GA or PS protocol. There was no difference in the primary endpoint, which was a composite of functional independence at 3 months and absence of any peri-procedural and medical complications during the first 7 days. The median mRS was 3 (2-5) under GA vs. 3 (2-4) under PS; RR 0.80 [95% CI: 0.53 to 1.22]. GA was strongly associated with the occurrence of arterial hypotension (87.4% vs. 44.9% in the PS group).

However, 1) these multicenter trials had relatively small sample sizes, 2) the time of assessment of the primary outcome measure was highly variable in GASS, and 3) in AMETIS, the BP targets in the GA group were not met and there was heterogeneity in drug management under PS and GA.

These contradictory results reveal a persistent clinical equipoise regarding this important issue.

The AMETIS-2 trial will evaluate almost every patient with anterior circulation large vessel occlusion stroke eligible for MT in different French comprehensive stroke centers.

The trial protocol for PS and GA will use dedicated anesthetic and hemodynamic management protocols.

The primary outcome measure will use an ordinal shift analysis of the mRS score evaluated at 3 months as the primary endpoint.

To extend the effect analysis, functional independence, cognitive and quality of life assessment will be evaluated as secondary endpoints at 3 months.

We therefore hypothesize that, with a dedicated anesthetic protocol and strict hemodynamic control, GA will lead to a better long-term functional outcome after stroke.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Acute ischemic stroke with an occlusion of the intracranial internal carotid artery and/or the proximal middle cerebral artery (M1-M2) with or without association of extracranial occlusion of the cervical internal carotid artery (tandem lesion)
  • Eligible for mechanical thrombectomy according to international guidelines
  • Informed and signed consent of patient, or if he is unable to consent the consent of patient's relative or emergency procedure in the absence of relative
  • National health insurance

Exclusion criteria

  • Coma or altered vigilance defined as a score ≥ 2 on the level of consciousness 1A subscale of the NIHSS
  • Premorbid disability defined as a mRS > 2
  • Posterior circulation stroke
  • Associated cerebral hemorrhage
  • Stroke complicating another acute illness or postoperative stroke
  • Emesis at arrival in angiosuite
  • Allergy to anesthetic medication
  • Pregnant or breast-feeding women
  • Adult under the protection of the law

Treatment and study plan

General Anesthesia

Procedure

In the general anesthesia (GA) group with tracheal intubation : Clinical target: unarousable state Standard preoxygenation, • Rapid sequence induction of GA will use intravenous Etomidate (0.2-0.3mg/Kg) or Ketamine (1-2mg/Kg) and Succinylcholine (1mg/Kg) or Rocuronium (1.2 mg/Kg) • Maintenance of GA will use intravenous Propofol (brain tissue target controlled infusion up to 4.0 µg/mL or up to 5.0 mg/kg/hr) or Sevoflurane (end-tidal concentration up to 2% (EtSevo)) and intravenous Remifentanil (brain tissue target controlled infusion up to 4.0 ng/mL) Movement despite unarousable state: NMBA as needed

Other names: GA

Procedural sedation

Procedure

In the procedural sedation group with spontaneous ventilation :

Clinical target: alert and "confortable" i.e. minimal to moderate sedation level

  • Subcutaneous local anesthesia with Lidocaine 10mg/mL (maximum 10mL)
  • Intravenous Remifentanil as necessary to achieve the sedation clinical target (brain tissue target controlled infusion up to 2.0 ng/mL). Propofol could be added as necessary (brain tissue target controlled infusion up to 3.0 µg/mL or 2.0 mg/kg/hr).

The lightest sedation level allowing the intervention has to be sought.

Other names: PS

Primary outcomes

  1. modified Rankin Scale

    Time frame: Day 90 after the stroke

    modified Rankin Scale, that range from 0 to 6: 0, no neurologic deficit; 1, no clinically significant disability; 2, slight disability; 3, moderate disability requiring some help; 4, moderately severe disability; 5, severe disability; 6, death

    > measured centrally by a blinded evaluator

Secondary outcomes

  1. Functional independence = key secondary outcome

    Time frame: Day 90 after the stroke

    Functional independence defined as a score of 0-2 on the rating of the modified Rankin Scale measured centrally by a blinded evaluator. This will be analyzed as a dichotomized measure

  2. Modified Treatment in Cerebral Infarction scale at the end of thrombectomy (mTICI).

    Time frame: At day 1 (end of the thrombectomy procedure)

    To assessed efficacy of GA vs PS

  3. Good quality of reperfusion defined as a mTICI score of 2b-3

    Time frame: At day 1 (end of the thrombectomy procedure)

    To assessed efficacy of GA vs PS

  4. Excellent quality of reperfusion defined as a mTICI score of 2c-3

    Time frame: At day 1 (end of the thrombectomy procedure)

    To assessed efficacy of GA vs PS

  5. National Institute of Health Stroke Scale (NIHSS)

    Time frame: At day 1 after the thrombectomy procedure

    To assessed efficacy of GA vs PS

  6. National Institute of Health Stroke Scale (NIHSS)

    Time frame: At day 7 after the thrombectomy procedure

    To assessed efficacy of GA vs PS

  7. Length of stay in stroke-unit and hospital

    Time frame: At day 90 after the thrombectomy procedure

    To assessed efficacy of GA vs PS

  8. moderate recovery defined as a score of 0-3 on the rating of the modified Rankin Scale

    Time frame: At day 90 after the thrombectomy procedure

    To assessed efficacy of GA vs PS

  9. Utility-weighted modified Rankin scale

    Time frame: At day 90 after the thrombectomy procedure

    To assessed efficacy of GA vs PS

  10. Barthel index

    Time frame: At day 90 after the thrombectomy procedure

    To assessed efficacy of GA vs PS

  11. Montreal Cognitive Assessment (MOCA)

    Time frame: At day 90 after the thrombectomy procedure

    To assessed efficacy of GA vs PS

  12. Stroke Specific Quality Of Life scale (SSQOL)

    Time frame: At day 90 after the thrombectomy procedure

    To assessed efficacy of GA vs PS

  13. Per-interventional arterial dissection or perforation defined as a flow-limiting tear or flap in the arterial wall or arterial extravasation of contrast media

    Time frame: At the end of the thrombectomy procedure

    To assessed safety of GA vs PS

  14. Per-interventional embolization in another territory defined as a new (not present on the first angiogram) arterial occlusion outside of the middle cerebral artery territory

    Time frame: At the end of the thrombectomy procedure

    To assessed safety of GA vs PS

  15. Procedural hypotension, hypertension, blood pressure variability, hypoxemia and aspiration (Yes or No)

    Time frame: At the end of the thrombectomy procedure

    To assessed safety of GA vs PS

  16. Hemodynamic protocol adherence

    Time frame: At day 1 after the thrombectomy procedure

    To assessed safety of GA vs PS

  17. Post-interventional groin hematoma defined as an accumulation of blood at the puncture site requiring evacuation, transfusion, or extended hospital stay

    Time frame: At day 7 after the thrombectomy procedure

    To assessed safety of GA vs PS

  18. Intracranial hemorrhage

    Time frame: At day 1 after the thrombectomy procedure

    To assessed safety of GA vs PS

  19. medical complications (could be evaluated before day 7 if the patient quit the hospital)

    Time frame: At day 7 after the thrombectomy procedure

    To assessed safety of GA vs PS

  20. Mortality

    Time frame: At day 7 after the thrombectomy procedure

    To assessed safety of GA vs PS

  21. Mortality

    Time frame: At day 90 after the thrombectomy procedure

    To assessed safety of GA vs PS

Study contacts

Contact information is provided by the study sponsor or research team.

Lise Laclautre

CONTACT

[email protected]

334.73.754.963

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Collaborators

  • ANARLF Network
  • PHRC, Ministry of Health France
  • STROKELINK

Registry information

Official study title

General Anesthesia Versus Procedural Sedation in Endovascular Therapy for Anterior Circulation Large Vessel Occlusion Stroke: A Multicenter Prospective Randomized Trial

Acronym: AMETIS 2

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Nov 19, 2025
Registry last updated
Nov 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.